Semaglutide Linked to Fewer Bone Fractures Despite Greater Weight Loss in Type 2 Diabetes Patients
A recent real-world study suggests that semaglutide, known by brand names such as Ozempic, Wegovy, and Rybelsus, may offer an added benefit for individuals with type 2 diabetes. The research indicates that patients using semaglutide experienced fewer bone fractures even while achieving more significant weight loss. The study, which analyzed health records from nearly 60,000 adults, found that those on semaglutide had approximately 15% fewer fractures compared to individuals taking other common weight-loss medications.
A large-scale, real-world study has indicated a potential unexpected benefit of semaglutide for people diagnosed with type 2 diabetes. The medication, commonly known under brand names like Ozempic, Wegovy, and Rybelsus, has been linked to stronger protection against bone fractures, even as it facilitates greater weight loss.
Researchers conducted an analysis of health records belonging to nearly 60,000 adults. Their findings revealed that participants who were prescribed semaglutide experienced approximately 15% fewer fractures. This outcome was observed despite these individuals also achieving greater weight reduction compared to those who were using other prevalent weight-loss medications.
According to Science Daily, these observations suggest a potential dual advantage for semaglutide users with type 2 diabetes, encompassing both weight management and skeletal health.
